Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Trial Profile

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2013 New source identified and integrated (ECOG2810: Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
    • 29 Nov 2012 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top